^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IM96 CAR-T cells

    i
    Other names: IM96 CAR-T cells
    Company:
    Beijing Imunopharm
    Drug class:
    GUCY2C-targeted CAR-T immunotherapy
    Related drugs:
    18d
    Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer (clinicaltrials.gov)
    P1, N=9, Recruiting, Beijing Immunochina Medical Science & Technology Co., Ltd.
    New P1 trial • CAR T-Cell Therapy • Metastases
    |
    cyclophosphamide • IM96 CAR-T cells
    over1year
    Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer (ESMO 2023)
    Pts were pre-treated with fludarabine and cyclophosphamide, and received a single infusion of IM96 at the dose of 3×108 (DL1), 6×108 (DL2), 12×108 (DL3), or 20×108 (DL4) CAR-T cells...The clinical response is correlated with tumor GCC expression, infusion dose, and CAR-T expansion level. This study is ongoing, and dose extensive investigation will also be performed.
    Clinical • P1 data • IO biomarker • Metastases
    |
    IL6 (Interleukin 6)
    |
    cyclophosphamide • fludarabine IV • IM96 CAR-T cells